Scarica l'app Stockscreener
13.00
5.93%
-0.82
Dopo l'orario di chiusura:
13.00
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus PT from Analysts - Defense World
Bicara Therapeutic, Inc. announced that it has received $108.234983 million in funding from a group of investors - Marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Receives Outperform Rating from Wedbush - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 8.6%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Up 7.3%Should You Buy? - MarketBeat
Wedbush Reiterates Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Announces First Patients Enrolled in - GlobeNewswire
Major Cancer Treatment Breakthrough? Phase 2/3 Trial Launches for Advanced Head & Neck Cancer - StockTitan
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to Strong-Buy at Wedbush - MarketBeat
Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Tuesday - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Wedbush - MarketBeat
Wedbush Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Wedbush Upgrades Bicara Therapeutics (NASDAQ:BCAX) to “Strong-Buy” - Armenian Reporter
Bicara Therapeutics (BCAX) to Release Earnings on Tuesday - MarketBeat
Wedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform Recommendation - Nasdaq
Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target - Marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 9.7%Should You Buy? - MarketBeat
Bicara reports positive Phase 1/1b trial results for cancer therapy - MSN
Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me (NASDAQ:BCAX) - Seeking Alpha
H.C. Wainwright lifts Bicara stock target to $45, maintains buy - MSN
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowTime to Sell? - MarketBeat
Bicara Therapeutics price target raised to $45 from $42 at H.C. Wainwright - MSN
Bicara Therapeutics Presents Phase 1/1B Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal At the 2025 Asco Gastrointestinal Cancers Symposium - Marketscreener.com
Stifel maintains Buy on Bicara stock with $47 target By Investing.com - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00 at HC Wainwright - Defense World
Bicara reports positive Phase 1/1b trial results for cancer therapy By Investing.com - Investing.com South Africa
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up After Analyst Upgrade - Defense World
Bicara Therapeutics Presents Phase 1/1b Dose Expansion - GlobeNewswire
Stifel maintains Buy on Bicara stock with $47 target - Investing.com India
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up on Analyst Upgrade - MarketBeat
H.C. Wainwright lifts Bicara stock target to $45, maintains buy By Investing.com - Investing.com Australia
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00 - MarketBeat
Cantor Fitzgerald Weighs in on BCAX FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on BCAX FY2025 Earnings - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.00 Average Price Target from Analysts - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month LowHere's What Happened - MarketBeat
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):